LncRNA GHET1 Predicts a Poor Prognosis of the Patients with Non-small Cell Lung Cancer
Overview
Pharmacology
Toxicology
Affiliations
Objective: Long non-coding RNAs (LcRNAs) is related to lung cancer progression. This study aimed at exploring lncRNA GHET1 in non-small cell lung cancer (NSCLC).
Patients And Methods: RT-PCR was used to detect lncRNA GHET1 expression in lung cancer specimen and cancer-adjacent areas. Kaplan-Meier assay was applied to investigate the prognosis of the patients with lung cancer.
Results: The expression of lncRNA GHET1 in lung cancer specimen was significantly higher than that in the cancer-adjacent tissues, which was related to the tumor size, differentiation degree of tumor cells, and lymph node metastasis of clinical specimens. Moreover, lncRNA GHET1 predicted a poor prognosis for the patients with lung cancer.
Conclusions: LncRNA GHET1 might be a biomarker and molecular target of NSCLC, providing a potential therapeutic target of NSCLC.
A novel glycosyltransferase-related lncRNA signature correlates with lung adenocarcinoma prognosis.
Bian C, Sun X, Huang J, Zhang W, Mu G, Wei K Front Oncol. 2022; 12:950783.
PMID: 36059686 PMC: 9434379. DOI: 10.3389/fonc.2022.950783.
Pyroptosis-Related LncRNA Signatures Correlate With Lung Adenocarcinoma Prognosis.
Huang H, Shi Z, Li Y, Zhu G, Chen C, Zhang Z Front Oncol. 2022; 12:850943.
PMID: 35311148 PMC: 8924059. DOI: 10.3389/fonc.2022.850943.
Long non-coding RNA GHET1 promotes thyroid cancer cell proliferation and invasion.
Liu Y, Shi P, Fang H, Zhao Z, Yang F, Zhang J Transl Cancer Res. 2022; 10(9):4148-4157.
PMID: 35116711 PMC: 8797618. DOI: 10.21037/tcr-21-1615.
Zhou X, Fan Y, He Y, Mou A, Wang F, Liu Y J Oncol. 2020; 2020:6341093.
PMID: 32908508 PMC: 7471811. DOI: 10.1155/2020/6341093.
Ding S, Huang H, Xu Y, Shen L, Zhong C, Zheng S Biomed Res Int. 2020; 2020:1648419.
PMID: 32420320 PMC: 7201585. DOI: 10.1155/2020/1648419.